KOSDAQSemiconductors036810

Fine Semitech

₩22,100▼ 0.45%2026-11-18 close
Market Cap
₩478.5B
Turnover
₩2.2B
Volume
100K
Shares out.
21.7M
PER
—
PBR
2.0×
EPS
-₩290
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Pellicle and chiller growth, profit turnaround still pending

Fine Semitech's revenue grew for two straight years through 2025, but operating profit turned to an operating loss in the third quarter of 2026 after a second-quarter profit, so whether earnings can hold is the central question.

  1. 1

    Revenue rose to KRW 237.4 billion in 2024 (up 20.1% YoY) and KRW 280.3 billion in 2025 (up 18.1% YoY), growing two years in a row.

  2. 2

    The company posted an operating loss of KRW 547 million and a parent-shareholder net loss of KRW 12.3 billion in 2025, with an operating margin of -0.2%.

  3. 3

    Operating profit reached KRW 9.62 billion in the second quarter of 2026 but turned to an operating loss of KRW 3.68 billion in the third quarter.

  4. 4

    A reported 80% domestic share in semiconductor pellicles and expected chiller order growth are cited as strengths, while the debt-to-equity ratio rose to 122.9% at the end of 2025.

02

Business structure

Fine Semitech was founded in 1987 as a maker of pellicles and chillers used in semiconductor processes.

The company mainly produces pellicles and chillers, and through subsidiaries it makes pellicle frames, multilayer ceramic substrates, silicon carbide semiconductor parts and conductive paste for electronic components.

In 2024 it acquired IMD, a producer of paste raw materials for electronic components, widening its materials business. Operations are reported in two areas, materials (including pellicles) and equipment (including chillers), and securities research also estimates earnings along these two lines.

A pellicle is a film that protects photomasks from contamination during lithography. According to wisereport company data as of September 2025, the company holds an 80% domestic share of semiconductor pellicles and 60% of FPD pellicles.

A ThinkPool research summary says chillers hold more than a 50% share within the infrastructure equipment vendor of a major customer. The company is developing pellicles for EUV processes and has completed development of EUV pellicle mounting and demounting equipment and inspection equipment.

Some products moved into sales in 2023 after customer demonstrations. R&D spending in 2024 was KRW 18.16 billion, equal to 7.65% of revenue on a consolidated basis. The new T-line at the Osan plant was completed in December 2024.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩65.5B-₩1.9B−2.9%
2025Q4₩70.3B-₩3.2B−4.5%
2026Q1₩69.6B₩1.4B2.0%
2026Q2₩89.3B₩9.6B10.8%
2026Q3₩91.2B-₩3.7B−4.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩223.4B₩6.2B₩44.1B2.8%18.1%60.6%
2023₩197.6B-₩10.8B-₩13.6B−5.5%−5.7%70.5%
2024₩237.4B₩2.3B₩1.5B1.0%0.6%107.3%
2025₩280.3B-₩500M-₩12.3B−0.2%−5.1%122.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue fell from KRW 223.4 billion in 2022 to KRW 197.6 billion in 2023 (down 11.5% YoY) and then rose to KRW 237.4 billion in 2024 (up 20.1% YoY) and KRW 280.3 billion in 2025 (up 18.1% YoY).

Revenue grew for two years in a row, from 2024 through 2025, and 2025 was the largest year of the 2022–2025 period while 2023 was the smallest.

Operating profit moved from KRW 6.18 billion in 2022 to an operating loss of KRW 10.8 billion in 2023 (a turn to loss from the prior year), then to operating profit of KRW 2.29 billion in 2024 (a turn to profit), and back to an operating loss of KRW 547 million in 2025 (a turn to loss).

The operating margin was 2.8% in 2022, -5.5% in 2023, 1.0% in 2024 and -0.2% in 2025, so revenue growth did not translate into margin recovery.

Net income attributable to controlling shareholders went from KRW 44.1 billion in 2022 to a loss of KRW 13.6 billion in 2023, a profit of KRW 1.45 billion in 2024, and a loss of KRW 12.3 billion in 2025.

Net income including non-controlling interests was a loss of KRW 14.3 billion in 2025, a larger loss than the parent-shareholder figure.

A ThinkPool research summary attributed the 2025 revenue increase to expanded DUV pellicle sales and new customers, and said the widened net loss mainly reflected equity-method losses from associates.

By quarter, revenue was KRW 65.5 billion in the third quarter of 2025, KRW 89.3 billion in the second quarter of 2026 and KRW 91.2 billion in the third quarter of 2026, rising for two consecutive quarters from the second quarter of 2026.

Operating profit was KRW 1.42 billion in the first quarter of 2026 (a turn to profit), KRW 9.62 billion in the second quarter (up 577.3% QoQ), and an operating loss of KRW 3.68 billion in the third quarter (a turn to loss QoQ).

Net income attributable to controlling shareholders was a profit of KRW 7.32 billion in the second quarter of 2026 and a loss of KRW 7.9 billion in the third quarter.

The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 6.01 billion.

The debt-to-equity ratio rose from 60.6% in 2022 to 122.9% in 2025, with total equity of KRW 242.3 billion at year-end 2025 (of which KRW 241.3 billion attributable to controlling shareholders) and total liabilities of KRW 297.8 billion.

Operating cash flow turned positive at KRW 14.1 billion in 2025 after KRW -5.39 billion in 2024. FnGuide's company summary notes that a rise in one-off costs is limiting profitability.

05

Industry analysis

A common backdrop for the industry is rising demand for advanced semiconductors, including AI data center servers and HBM, which is increasing use of higher-value products according to FnGuide's company summary. The same summary also points out that a rise in one-off costs is constraining profitability.

Pellicles protect photomasks in lithography, so their demand is tied to chip production volumes and shifts in process generations. The EUV pellicles the company is developing could change its business structure depending on customer demand and the timing of commercialization.

Chillers manage temperature in process equipment, and a ThinkPool research summary links the expansion of investment at Pyeongtaek P4 and the Hwaseong plant to rising orders.

The same summary also outlined a scenario in which supply-chain disruptions for global components bring forward Pyeongtaek P4 East and P5 investment, or additional orders for eco-friendly chillers for the Taylor fab in the United States, could push equipment results above estimates.

Industry peers include equipment listed companies such as HANMI Semiconductor, Jusung Engineering and Wonik IPS, and materials listed companies such as Soulbrain and Dongjin Semichem.

The pellicle business holds a relatively high domestic share, but because the company combines equipment and materials, segment results may move differently through the cycle. In 2025, equity-method losses from associates widened the net loss, so non-core items affected results during that period.

06

Outlook

A ThinkPool research summary projects 2026 chiller revenue of KRW 124.0 billion, up 11.3% YoY. The same summary expects 2026 revenue in the materials division of KRW 188.5 billion, up 13.3% YoY.

FnGuide's consensus shows 2026 revenue of KRW 307.0 billion, operating profit of KRW 23.1 billion and net income of KRW 13.0 billion, and for 2027 revenue of KRW 353.1 billion, operating profit of KRW 37.1 billion and net income of KRW 26.0 billion.

The 2026 consensus operating profit of KRW 23.1 billion is more than three times the sum of the operating results disclosed for the first through third quarters of 2026, which is about KRW 7.36 billion, so fourth-quarter profit will determine whether that path is achieved.

The expansion at Pyeongtaek and Hwaseong cited as the basis for chiller orders needs to convert into actual orders. In the materials business, it is worth watching whether pellicle sales growth continues and whether display or semiconductor pellicles drive it.

The EUV pellicle and the mounting and inspection equipment have completed development, but the commercialization timing and sales scale have not been disclosed. If raw material and component prices keep rising, the effect on gross margin also needs to be checked.

The 2026 annual report must be filed by the end of March 2027, when the direction of the annual operating margin and debt ratio will be confirmed again.

07

Valuation

PER
—
PBR
2.0×
ROE
-2.4%
EPS
-₩290
BPS
₩12,462
Dividend per share
₩0

The price-to-book ratio is above 1x, which means the stock trades at a premium to net asset value. Because the company posted a net loss over the last four quarters, its price-to-earnings ratio cannot be calculated. Dividends are effectively nil, so valuation interpretation based on dividend income is limited.

The operating margin was -0.2% in 2025, and after a profit in the second quarter of 2026 the company returned to an operating loss in the third quarter. Because profits are currently negative, comparisons with industry-average multiples will become more meaningful once earnings normalize.

Consensus points to profit expansion in 2026 and 2027, so market valuation will depend on whether those earnings assumptions are realized. Where the stock sits relative to its historical valuation band changes with price moves. Until earnings stabilize in profit, net asset value and earnings-based multiples are unlikely to move together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Domestic pellicle share base

The company holds an 80% domestic share of semiconductor pellicles and 60% of FPD pellicles, according to wisereport data as of September 2025. Rising demand for advanced chips, including AI data center servers and HBM, is cited as the backdrop for growth.

Pellicle sales expansion is tied to the DUV pellicle growth that a ThinkPool summary cited as a reason for 2025 revenue growth.

Expected chiller order growth

A ThinkPool research summary projects 2026 chiller revenue of KRW 124.0 billion, up 11.3% YoY. Expanded investment at the Pyeongtaek P4 and Hwaseong plants is cited as the driver of rising orders.

The same summary says the company holds more than half of chiller share within a major customer's infrastructure equipment vendor.

Quarterly momentum in 2026

Revenue reached KRW 89.3 billion in the second quarter of 2026 and KRW 91.2 billion in the third quarter, growing for two consecutive quarters. Operating profit in the second quarter was KRW 9.62 billion, up 577.3% QoQ, and net income attributable to controlling shareholders turned to a profit of KRW 7.32 billion.

Compared with the operating loss of KRW 1.87 billion in the third quarter of 2025, the quarterly profit structure improved in that period.

09

Bear factors

Recurring annual losses

The company posted an operating loss of KRW 547 million and a parent-shareholder net loss of KRW 12.3 billion in 2025. The operating margin fell to -0.2% in 2025 from 1.0% in 2024. Compared with 2.8% in 2022, profitability did not recover even as revenue grew.

Return to loss in the third quarter

The operating loss in the third quarter of 2026 was KRW 3.68 billion, a turn from the second quarter's profit, and the loss widened from the same quarter last year. Net loss attributable to controlling shareholders was KRW 7.9 billion.

Together with the KRW 3.16 billion operating loss in the fourth quarter of 2025, the sustainability of quarterly profit has not yet been confirmed.

Financial burden and associate losses

The debt-to-equity ratio rose from 60.6% in 2022 to 122.9% in 2025, with total liabilities of KRW 297.8 billion. The 2025 net loss of KRW 14.3 billion is attributed mainly to equity-method losses from associates, according to a ThinkPool summary. FnGuide's company summary notes that rising one-off costs constrain profitability.

10

Risk factors

Earnings volatility

Quarterly operating profit has shifted from a profit in the first quarter of 2026 to a wider profit in the second quarter and then a loss in the third, so earnings have not stabilized. On an annual basis the company posted operating losses in 2023 and 2025.

Because chiller and pellicle sales depend on specific customers and facility investment schedules, quarterly profit swings may widen.

Balance sheet and associates

Total liabilities at year-end 2025 were KRW 297.8 billion, above total equity of KRW 242.3 billion, for a debt-to-equity ratio of 122.9%. Equity-method losses from loss-making associates have widened the net loss before, so non-core items can affect results. Operating cash flow was positive at KRW 14.1 billion in 2025 but negative at KRW -5.39 billion in 2024.

Raw materials and technology transition

FnGuide's company summary points to rising one-off costs, including raw materials and components, as a constraint on profitability improvement. The EUV pellicle and related equipment have completed development, but their commercialization timing and sales scale have not been disclosed. If the pace of process transition differs from expectations, demand for the current sales mix could change.

11

What to watch next

  1. End of December 2026

    Fiscal year 2026 ends. The key check is how much of the gap between the operating profit disclosed through the third quarter and the 231 billion won full-year consensus is closed in the fourth quarter.

  2. Early 2027 (date TBD)

    Preliminary fourth-quarter 2026 results are expected. The checks are whether revenue growth since the second quarter continues and whether operating results return to profit.

  3. By end of March 2027

    The deadline for the 2026 annual report. The checks are how the annual operating margin and debt-to-equity ratio move from -0.2% and 122.9% in 2025, and how equity-method results from associates are recorded.

  4. During 2027 (timing TBD)

    The checks are whether Pyeongtaek P4 East and P5 investment and chiller orders convert into actual revenue, and whether EUV pellicle commercialization is disclosed.

12

Overall view

Fine Semitech has grown revenue two years in a row, in 2024 and 2025, supported by an 80% domestic share of semiconductor pellicles and expectations for chiller order growth.

However, it posted an operating loss of KRW 547 million and a parent-shareholder net loss of KRW 12.3 billion in 2025, and its operating margin stayed at -0.2%.

It returned to operating profit of KRW 9.62 billion in the second quarter of 2026, but slipped back to an operating loss of KRW 3.68 billion in the third quarter. The net loss attributable to controlling shareholders over the last four quarters totals KRW 6.01 billion.

The debt-to-equity ratio rose to 122.9%, and equity-method losses from associates are cited as a factor widening the net loss.

Consensus projects operating profit of KRW 23.1 billion for 2026 and KRW 37.1 billion for 2027, but the sum of operating results disclosed for the first through third quarters of 2026 falls short of that.

The key checkpoints are fourth-quarter profit, the annual operating margin and debt ratio in the 2026 annual report, and whether chiller orders convert into revenue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. alphasquare.co.kr
  5. ssl.pstatic.net
  6. ssl.pstatic.net
  7. m.thinkpool.com
  8. ssl.pstatic.net
  9. vegannews.co.kr
  10. vegannews.co.kr
  11. vegannews.co.kr
  12. vegannews.co.kr
  13. investing.com
  14. edaily.co.kr
  15. srtimes.kr
  16. kr.investing.com
  17. msn.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis